JPMorgan Asset Management Form 8.3 - Pfizer Inc (5035G)
21 November 2015 - 2:14AM
UK Regulatory
TIDMPFZ
RNS Number : 5035G
JPMorgan Asset Management
20 November 2015
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2007 (AS AMENDED)
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES
REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing JPMorgan Asset Management
(Note 1)
-------------------------------------- --------------------------
Company dealt in Pfizer Inc.
-------------------------------------- --------------------------
Class of relevant security Ordinary Shares
to which the dealings
being disclosed relate
(Note 2)
-------------------------------------- --------------------------
Date of dealing 19 November 2015
-------------------------------------- --------------------------
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the
class of relevant security dealt in (Note 3)
Long Short
--------------------------------- ------------------- -------------
Number (%) Number (%)
--------------------------------- ------------ ----- ------- ----
(1) Relevant securities 87,351,528* 1.42
--------------------------------- ------------ ----- ------- ----
(2) Derivatives (other
than options) 208,388 0.00
--------------------------------- ------------ ----- ------- ----
(3) Options and agreements
to purchase/sell
--------------------------------- ------------ ----- ------- ----
87,559,916
Total * 1.42
--------------------------------- ------------ ----- ------- ----
*In addition to the dealings in section 3, there is a reduction
in the holding of 184 shares due to a transfer.
(b) Interests and short positions in relevant securities of the
company, other than the class dealt in (Note 3)
Class of relevant security: Long Short
-------------------------------- ------------- -------------
Number (%) Number (%)
-------------------------------- ------- ---- ------- ----
(1) Relevant securities
-------------------------------- ------- ---- ------- ----
(2) Derivatives (other
than options)
-------------------------------- ------- ---- ------- ----
(3) Options and agreements
to purchase/sell
-------------------------------- ------- ---- ------- ----
Total
-------------------------------- ------- ---- ------- ----
3. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant Price per unit
securities (USD)
-------------- ------------------- ---------------
Purchase 118,756 32.1650 USD
Purchase 53 32.2472 USD
Purchase 41 32.2473 USD
Purchase 329 32.2565 USD
Purchase 227,840 32.8023 USD
Sale 492 31.9990 USD
Sale 162 32.0200 USD
Sale 111 32.0890 USD
Sale 99,600 32.1159 USD
Sale 4 32.1250 USD
Sale 3 32.1270 USD
Sale 20 32.1280 USD
Sale 50 32.1290 USD
Sale 4 32.1300 USD
Sale 27,500 32.1450 USD
Sale 551 32.1480 USD
Sale 2,620 32.1540 USD
Sale 13,500 32.1932 USD
Sale 44 32.2410 USD
Sale 63 32.2420 USD
Sale 31 32.2450 USD
Sale 10 32.2780 USD
Sale 27 32.2790 USD
Sale 36,932 32.2920 USD
Sale 38 32.2980 USD
Sale 89 32.2990 USD
Sale 29 32.3000 USD
Sale 156,218 32.3111 USD
Sale 50,784 32.3270 USD
Sale 130 32.4890 USD
Sale 14 32.4900 USD
Sale 165,400 32.6332 USD
Sale 44 32.6690 USD
Sale 25 32.8200 USD
Sale 2,040 32.8499 USD
Sale 15 32.8900 USD
Sale 252 32.8910 USD
Sale 112 32.8920 USD
Sale 4 32.8930 USD
-------------- ------------------- ---------------
(b) Derivatives transactions (other than options transactions)
Product name, Nature of transaction Number of relevant Price per unit
e.g. CFD (Note 6) securities (Note (Note 5)
7)
-------------- ---------------------- ------------------- ---------------
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, Writing, Number of Exercise Type, Expiry Option
e.g. call selling, securities price e.g. American, date money
option purchasing, to which European paid/received
varying the option etc. per unit
etc. relates (Note (Note 5)
7)
-------------- ------------- --------------- --------- ---------------- ------- ---------------
(ii) Exercising
Product name, e.g. Number of securities Exercise price per
call option unit (Note 5)
------------------- --------------------- -------------------
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction Details Price per unit (if
(Note 8) applicable) (Note
5)
---------------------- -------- -------------------
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options
or derivatives
Full details of any agreement, arrangement or understanding
between the person disclosing and any other person relating
to the voting rights of any relevant securities under
any option referred to on this form or relating to the
voting rights or future acquisition or disposal of any
relevant securities to which any derivative referred
to on this form is referenced. If none, this should
be stated.
-------------------------------------------------------------
Is a Supplemental Form 8 attached? NO
(Note 9)
Date of disclosure 20 November 2015
--------------------------------------------- ----------------------
Contact name Evangelos Galiatsatos
--------------------------------------------- ----------------------
Telephone number 0207 742 6148
--------------------------------------------- ----------------------
If a connected EFM, name of offeree/offeror N/A
with which connected
--------------------------------------------- ----------------------
If a connected EFM, state nature N/A
of connection (Note 10)
--------------------------------------------- ----------------------
The Notes on Form 8.3 can be viewed on the Panel's website at
www.irishtakeoverpanel.ie.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ISEBMBATMBBTBMA
(END) Dow Jones Newswires
November 20, 2015 10:14 ET (15:14 GMT)
Pfizer (LSE:PFZ)
Historical Stock Chart
From Oct 2024 to Nov 2024
Pfizer (LSE:PFZ)
Historical Stock Chart
From Nov 2023 to Nov 2024
